NTLA Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 82% planned / 18% discretionary
Largest single sale: $107.9K.
Where they traded
Last open-market purchase: January 5, 2026 , by Cohen Fred E .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| LEONARD JOHN M | President and CEO | Sell 10b5-1 | 9,000 | $11.99 | $107.9K | 1,138,064 −0.8% of holding | |
| Dube Michael P | VP, Chief Accounting Officer | Sell | 1,864 | $12.43 | $23.2K | 65,022 −2.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.